Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 159 for:    colon cancer AND Capecitabine AND Fluorouracil

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer (COBRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03451370
Recruitment Status : Recruiting
First Posted : March 1, 2018
Last Update Posted : March 1, 2018
Sponsor:
Information provided by (Responsible Party):
Istituto Oncologico Veneto IRCCS

Brief Summary:
  • Oxaliplatin-based doublets plus bevacizumab are standard first-line therapy options for patients (pts) with metastatic colorectal cancer (mCRC). Slight adjustments in chemo-dosage are commonly applied in routinely practice to elderly pts, but those modified schedules have never been standardized
  • The addition of oxaliplatin versus no oxaliplatin to treatment with 5-fluorouracil in older and frail untreated pts with mCRC resulted in a non-statistically significant trend toward improvement in Progression Free Survival (PFS) and a lack of benefit in Overall Survival (OS)
  • In elderly pts deemed unfit for an upfront combined chemotherapy a fluoropyrimide-based monotherapy plus bevacizumab is considered a reasonable first-line treatment
  • Clinical definition of elderly (over 70 years old) pts with CRC that may deserve a more or less intensive combination therapy is still debated. The cut-off of 75 years old combined with ECOG PS assessment is a reasonable approach for clearly defining candidates to different approaches
  • Several geriatric screening tools have been used to identify pts with a geriatric profile potentially predicting for overall survival and risk of toxicity. The G8 screening tool has been already validated in pts with cancer showing the strongest prognostic value for OS; the CRASH score is able to stratify pts according an estimated risk of treatment-related toxicities

On the basis of these considerations, we designed the present observational study of first-line therapy with bevacizumab in combination with capecitabine and oxaliplatin in previously untreated elderly pts affected by unresectable mCRC in order to evaluate its efficacy in real world practice (as measured by progression free survival)


Condition or disease Intervention/treatment
Elderly Metastatic Colorectal Cancer Patients Drug: Capecitabine Drug: Oxaliplatin Drug: Bevacizumab

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 121 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: First-line Combination of Capecitabine and Oxaliplatin + Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Capecitabine

    750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.

    To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.

    If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal.

  • Drug: Oxaliplatin
    100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
  • Drug: Bevacizumab

    7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.

    If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.



Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Up to 28 months ]
    PFS is defined as the time from study enrollment to the first documentation of objective disease progression or death due to any cause, whichever occurs first.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Elderly (> 70 years) patients with metastatic colorectal cancer
Criteria

Inclusion Criteria:

  • Histologically proven diagnosis of colorectal cancer.
  • Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
  • Indication to oxaliplatin, capecitabine and bevacizumab as first line treatment.
  • At least one measurable lesion according to RECIST1.1 criteria.
  • Availability of a tumoral sample (primary and/or metastatic sites).
  • Age ≥ 70 years.
  • ECOG PS (Eastern Cooperative Oncology Group - Performance Status) 1 or 2 for pts aged 70 to 75 years; ECOG PS 0 or 1 for pts aged > 75 years.
  • Life expectancy of at least 12 weeks.
  • Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.
  • Laboratory Requirements:

    • Neutrophils ≥1.5 x 109/L,
    • Platelets ≥100 x 109/L,
    • Hgb ≥ 9 g/dl.
    • Total bilirubin ≤ 1.5 time the upper-normal limits (UNL) of the normal values and ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases),
    • Alkaline phosphatase ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases),
    • Creatinine clearance ≥ 50 mL/min or serum creatinine ≤1.5 x UNL,
    • Urine dipstick of proteinuria <2+. Pts discovered to have 2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate <1 g of protein/24 hr.
  • Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (i.e. barrier contraceptive measure or oral contraception, total abstinence) during the study and until 6 months after the last treatment.
  • Geriatric assessment by means of G8 screening tool and CRASH score.
  • Written informed consent to study procedures and to molecular analyses before pts registration.
  • Will and ability to comply with the protocol.

Exclusion Criteria:

criteria

  • Previous adjuvant oxaliplatin-containing chemotherapy.
  • Previous treatment with bevacizumab.
  • Previous systemic treatment for the metastatic disease.
  • Previous radiotherapy treatment to any site within 4 weeks before the study.
  • Evidence of untreated brain metastases or spinal cord compression or primary brain tumours.
  • History or evidence upon physical examination of CNS disease unless adequately treated.
  • Symptomatic peripheral neuropathy > 1 grade NCIC-CTG criteria.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • Evidence of bleeding diathesis or coagulopathy.
  • Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy.
  • Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.
  • Any previous venous thromboembolism > NCI CTCAE Grade 3.
  • History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
  • Current ongoing treatment with anticoagulants for therapeutic purposes.
  • Chronic, daily treatment with high-dose aspirin (>325 mg/day).
  • Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration or putting the patient at high risk for treatment-related toxicities.
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
  • Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
  • Contraindications for the use of corticosteroids and antihistamines as premedication or known hypersensitivity to any other component of the study drugs.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03451370


Contacts
Layout table for location contacts
Contact: Sara Lonardi +39 049/8217927 sara.lonardi@iov.veneto.it
Contact: Federica Buggin +39 049/8217927 federica.buggin@iov.veneto.it

Locations
Layout table for location information
Italy
Istituto Oncologico Veneto IRCCS Recruiting
Padua, Italy, 35128
Contact: Federica Buggin       federica.buggin@iov.veneto.it   
Principal Investigator: Sara Lonardi, MD         
Sub-Investigator: Fotios Loupakis, MD         
Sponsors and Collaborators
Istituto Oncologico Veneto IRCCS

Additional Information:

Layout table for additonal information
Responsible Party: Istituto Oncologico Veneto IRCCS
ClinicalTrials.gov Identifier: NCT03451370     History of Changes
Other Study ID Numbers: COBRA
First Posted: March 1, 2018    Key Record Dates
Last Update Posted: March 1, 2018
Last Verified: February 2018

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Istituto Oncologico Veneto IRCCS:
Bevacizumab
Capecitabine
Oxaliplatin
CRASH score
ECOG PS
G8 score
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Capecitabine
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Oxaliplatin
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action